Johnson & Johnson 13F annual report
Johnson & Johnson is an investment fund managing more than $401 billion ran by Marc Larkins. There are currently 20 companies in Mr. Larkins’s portfolio. The largest investments include Protagonist Therapeutics Inc and Rapport Therapeutics, Inc., together worth $143 billion.
$401 billion Assets Under Management (AUM)
As of 2nd August 2024, Johnson & Johnson’s top holding is 2,449,183 shares of Protagonist Therapeutics Inc currently worth over $84.9 billion and making up 21.2% of the portfolio value.
Relative to the number of outstanding shares of Protagonist Therapeutics Inc, Johnson & Johnson owns more than approximately 0.1% of the company.
In addition, the fund holds 2,498,051 shares of Rapport Therapeutics, Inc. worth $58.1 billion.
The third-largest holding is Cvrx, Inc. worth $49.2 billion and the next is Legend Biotech Corp worth $36.1 billion, with 814,586 shares owned.
Currently, Johnson & Johnson's portfolio is worth at least $401 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Johnson & Johnson
The Johnson & Johnson office and employees reside in New Brunswick, New Jersey. According to the last 13-F report filed with the SEC, Marc Larkins serves as the Secretary at Johnson & Johnson.
Recent trades
In the most recent 13F filing, Johnson & Johnson revealed that it had opened a new position in
Rapport Therapeutics, Inc. and bought 2,498,051 shares worth $58.1 billion.
On the other hand, there are companies that Johnson & Johnson is getting rid of from its portfolio.
Johnson & Johnson closed its position in Kenvue Inc. on 9th August 2024.
It sold the previously owned 182,329,550 shares for $3.91 trillion.
One of the smaller hedge funds
The two most similar investment funds to Johnson & Johnson are Sierra Summit Advisors and Icon Advisers Inc/co. They manage $401 billion and $401 billion respectively.
Marc Larkins investment strategy
Johnson & Johnson’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 52.9% of
the total portfolio value.
The fund focuses on investments in the United States as
45.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
5% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.46 billion.
The complete list of Johnson & Johnson trades based on 13F SEC filings
These positions were updated on August 9th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Kenvue Inc. |
Closed
182,329,550
|
$3,912,792,143,000 | |
| Protagonist Therapeutics Inc |
No change
2,449,183
|
$84,864,191,000 | 21.18% |
| Fusion Pharmaceuticals Inc. |
Closed
3,670,516
|
$78,255,401,000 | |
| Rapport Therapeutics, Inc. |
Opened
2,498,051
|
$58,104,666,000 | 14.50% |
| Shockwave Medical Inc. |
Closed
166,812
|
$54,318,992,000 | |
| Cvrx, Inc. |
No change
4,103,430
|
$49,200,126,000 | 12.28% |
| Legend Biotech Corp |
No change
814,586
|
$36,078,014,000 | 9.00% |
| Contineum Therapeutics Inc. |
Opened
1,979,173
|
$34,853,237,000 | 8.70% |
| Nanobiotix S.A. |
No change
5,623,816
|
$28,119,080,000 | 7.02% |
| MeiraGTx Holdings plc |
No change
6,641,064
|
$27,958,879,000 | 6.98% |
| Procept Biorobotics Corporation |
No change
357,939
|
$21,866,494,000 | 5.46% |
| Neumora Therapeutics, Inc. |
No change
1,849,445
|
$18,180,044,000 | 4.54% |
| Xencor Inc |
No change
748,062
|
$14,160,814,000 | 3.53% |
| Fate Therapeutics Inc |
No change
3,379,064
|
$11,083,330,000 | 2.77% |
| Arrowhead Pharmaceuticals Inc. |
No change
247,598
|
$6,435,072,000 | 1.61% |
| Rallybio Corporation |
Opened
3,636,363
|
$4,872,726,000 | 1.22% |
| Nano-X Imaging Ltd. |
No change
158,852
|
$1,165,974,000 | 0.29% |
| Vor Biopharma, Inc. |
No change
1,074,658
|
$1,074,658,000 | 0.27% |
| Aldeyra Therapeutics Inc |
No change
299,669
|
$991,904,000 | 0.25% |
| BiomX Inc |
No change
1,923,201
|
$646,388,000 | 0.16% |
| Standard BioTools Inc |
No change
311,967
|
$552,182,000 | 0.14% |
| Adicet Bio, Inc. |
No change
364,472
|
$441,011,000 | 0.11% |
| Clearside Biomedical Inc |
Closed
169,629
|
$259,532,000 | |
| TRACON Pharmaceuticals Inc |
Closed
84,003
|
$36,104,000 | |
| Senseonics Holdings Inc |
No change
54,621
|
$21,794,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 25 holdings | |||
Hedge funds similar to Johnson & Johnson
- Sycamore Partners Management, L.P.
- Galibier Capital Management
- Legacy Trust
- True Wealth Design
- Woodard & Co Asset Management Group Inc adv
- Icon Advisers Inc/co
- Sierra Summit Advisors
- Gravity Asset Management
- Bleichroeder L.P.
- Juniper Hill Capital Management L.P.
- Adw Capital Management
- Waypoint Capital Advisors
- Origin Asset Management LL.P.
- Warwick Investment Management